NCT03031353

Misoprostol Before Elective Caesarean Section for Decreasing the Neonatal Respiratory Morbidity

Misoprostol Before Elective Caesarean Section for Decreasing the Neonatal Respiratory Morbidity: A Randomized Controlled Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 170 (estimated)
• Sponsor: Ain Shams University · Academic / Other
• Sex: Female
• Age: 18 Years – 35 Years
• Healthy volunteers: Not accepted

Summary

Neonatal respiratory distress may occur in either term or preterm newborns with a higher relative risk in preterm, and whether born vaginally or through caesarean section, but in a higher percentage after elective caesarean section whose rate is rising. Prostaglandins may be given about one hour before an elective caesarean section after excluding the presence of contraindication to their use to decrease the neonatal respiratory diseases and thus, the number of children who suffered from bronchopulmonary dysplasia that occurs frequently in children who had previously TTN will diminish.

Conditions

• Transient Tachypnea Newborn
• Cesarean Delivery Affecting Fetus

Interventions

Type	Name	Description
DRUG	Misoprostol	Misoprostol is given before elective cesarean section as prophylaxis against post partum hemorrhage
DRUG	Placebos	placebos tablet will be given before elective Cesarean sections

Timeline

• Start date: 2017-01-01
• Primary completion: 2018-05-01
• Completion: 2018-06-01
• First posted: 2017-01-25
• Last updated: 2018-05-29

Locations

1 site across 1 country: Egypt